Outcomes

The available evidence on Melanotan II outcomes is extremely limited and primarily consists of case reports, animal studies, and one ongoing clinical trial. The strength of evidence is very weak overall.

Clinical Outcomes in Humans

Safety Concerns:

Case reports describe oral mucosa changes associated with Melanotan II injections, though specific details of these changes are not provided in the available abstracts
One case report suggests a possible association with oral mucosal malignant melanoma following nasal spray use, though causality cannot be established from a single case

Therapeutic Effects:

One Phase 2 clinical trial is currently recruiting patients to evaluate Melanotan II as an adjunct to phototherapy for vitiligo repigmentation, but no results are yet available

Preclinical Outcomes

Behavioral Effects (Animal Studies):

In male rats subjected to chronic stress, synthetic analogs including Melanotan II demonstrated antidepressant-like and anti-stress effects, though the specific magnitude and clinical relevance of these effects are unclear

Metabolic Effects:

Animal studies suggest involvement in metabolic regulation and feeding behavior, particularly through effects on melanocortin receptors, but specific outcome measures and effect sizes are not detailed in available abstracts

Evidence Limitations

The current literature provides insufficient evidence to draw meaningful conclusions about Melanotan II's therapeutic efficacy or safety profile. Most studies are either preclinical, case reports, or ongoing trials without published results. No controlled human studies with measurable clinical endpoints have been completed and published in the available evidence.

This information is for educational purposes only and should not be considered medical advice. Consult a healthcare provider before considering any treatment.

Melanotan II

Member access required